Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Ksenija Nesic(The University of Melbourne), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Nicola Waddell(QIMR Berghofer Medical Research Institute), Cassandra J. Vandenberg(The University of Melbourne), Inger Olesen(Barwon Health), Elizabeth Lieschke(The University of Melbourne), Maria I. Harrell(Johns Hopkins University), Olga Kondrashova(QIMR Berghofer Medical Research Institute), Alexander Dobrovic(The University of Melbourne), Anna DeFazio(The University of Sydney), David D.L. Bowtell(The University of Melbourne), Damien Kee(Peter MacCallum Cancer Centre), Zi Qing Chai(Olivia Newton-John Cancer Wellness & Research Centre), Kristy Shield‐Artin(The University of Melbourne), Mohammad Reza Eftekhariyan Ghamsari(Olivia Newton-John Cancer Wellness & Research Centre), Scott H. Kaufmann(Mayo Clinic), Cordelia D. McGehee(Mayo Clinic), Gwo‐Yaw Ho(The University of Melbourne), Nirashaa Bound(Walter and Eliza Hall Institute of Medical Research), Marc R. Radke(University of Washington), Rachel M. Hurley(Mayo Clinic), Genevieve Dall(The University of Melbourne), Ashan Musafer(Olivia Newton-John Cancer Wellness & Research Centre), Elizabeth M. Swisher(University of Washington), Kátia Nones(QIMR Berghofer Medical Research Institute), S. John Weroha(Mayo Clinic), Orla McNally(Royal Women's Hospital), Nadia Traficante(The University of Melbourne), Australian Ovarian Cancer Study(QIMR Berghofer Medical Research Institute), Matthew J. Wakefield(The University of Melbourne)
Cited by 91
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k